Semler Scientific had its Relative Strength (RS) Rating upgraded from 66 to 76 Thursday — a welcome improvement, but still below the 80 or better score you look for.
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Semler Scientific can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Semler Scientific is now considered extended and out of buy range after clearing a 29.93 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
In terms of top and bottom line numbers, the company has posted rising EPS growth in each of the last two reports. Revenue gains have not followed the same trajectory, coming in at -18% in the most recent quarterly report.
The company earns the No. 32 rank among its peers in the Medical-Products industry group. Boston Scientific, Penumbra and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
